日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Response Rate, Event-Free Survival, and Overall Survival in Newly Diagnosed Acute Myeloid Leukemia: US Food and Drug Administration Trial-Level and Patient-Level Analyses

新诊断急性髓系白血病患者的缓解率、无事件生存期和总生存期：美国食品药品监督管理局试验层面和患者层面的分析

期刊:Journal of Clinical Oncology
影响因子:41.9
doi:10.1200/JCO.21.01548
Norsworthy, Kelly J; Gao, Xin; Ko, Chia-Wen; Pulte, E Dianne; Zhou, Jiaxi; Gong, Yutao; Shen, Yuan Li; Vallejo, Jonathon; Gwise, Thomas E; Sridhara, Rajeshwari; Deisseroth, Albert B; Farrell, Ann T; de Claro, R Angelo; Blumenthal, Gideon M; Pazdur, Richard
白血病
发表日期：2022
文献求助 收藏

Differentiation Syndrome with Ivosidenib and Enasidenib Treatment in Patients with Relapsed or Refractory IDH-Mutated AML: A U.S. Food and Drug Administration Systematic Analysis

伊沃西尼布和恩西地尼布治疗复发或难治性IDH突变型急性髓系白血病患者发生分化综合征：美国食品药品监督管理局的系统分析

期刊:Clinical Cancer Research
影响因子:10.2
doi:10.1158/1078-0432.CCR-20-0834
Norsworthy, Kelly J; Mulkey, Flora; Scott, Emma C; Ward, Ashley F; Przepiorka, Donna; Charlab, Rosane; Dorff, Sarah E; Deisseroth, Albert; Kazandjian, Dickran; Sridhara, Rajeshwari; Beaver, Julia A; Farrell, Ann T; de Claro, R Angelo; Pazdur, Richard
白血病
发表日期：2020
文献求助 收藏

FDA Approval Summary: Ruxolitinib for Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease

FDA批准摘要：鲁索替尼用于治疗类固醇难治性急性移植物抗宿主病

期刊:Oncologist
影响因子:4.2
doi:10.1634/theoncologist.2019-0627
Przepiorka, Donna; Luo, Lola; Subramaniam, Sriram; Qiu, Junshan; Gudi, Ramadevi; Cunningham, Lea C; Nie, Lei; Leong, Ruby; Ma, Lian; Sheth, Christopher; Deisseroth, Albert; Goldberg, Kirsten B; Blumenthal, Gideon M; Pazdur, Richard
发表日期：2020
文献求助 收藏

U.S. Food and Drug Administration Benefit-Risk Assessment of Nilotinib Treatment Discontinuation in Patients with Chronic Phase Chronic Myeloid Leukemia in a Sustained Molecular Remission

美国食品药品监督管理局对持续分子缓解的慢性期慢性粒细胞白血病患者停用尼洛替尼治疗的获益风险评估

期刊:Oncologist
影响因子:4.2
doi:10.1634/theoncologist.2018-0759
Pulte, E Dianne; Wroblewski, Tanya; Bloomquist, Erik; Tang, Shenghui; Farrell, Ann; Deisseroth, Albert; McKee, Amy E; Pazdur, Richard
白血病
细胞生物学
粒细胞
发表日期：2019
文献求助 收藏

Use of adenoviral vectors to target chemotherapy to tumor vascular endothelial cells suppresses growth of breast cancer and melanoma.

利用腺病毒载体将化疗药物靶向肿瘤血管内皮细胞，可抑制乳腺癌和黑色素瘤的生长

期刊:Molecular Therapy
影响因子:12
doi:10.1038/mt.2010.5
Li Pingchuan, Liu Yanzheng, Maynard Jonathan, Tang Yucheng, Deisseroth Albert
肿瘤
乳腺癌
黑色素瘤
Viral
发表日期：2010
文献求助 收藏

Use of CD40L immunoconjugates to overcome the defective immune response to vaccines for infections and cancer in the aged

利用CD40L免疫偶联物克服老年人对感染和癌症疫苗的免疫反应缺陷

期刊:Cancer Immunology Immunotherapy
影响因子:5.1
doi:10.1007/s00262-009-0718-3
Tang, Yu Cheng; Thoman, Marilyn; Linton, Phyllis-Jean; Deisseroth, Albert
肿瘤
T细胞
肿瘤免疫
炎症/感染
CD40
CD4
免疫/内分泌
发表日期：2009
文献求助 收藏

International Society for Cell and Gene Therapy of Cancer (ISCGT) annual meeting: conference overview and introduction to the symposium papers

国际癌症细胞与基因治疗学会（ISCGT）年会：会议概述及专题研讨会论文介绍

期刊:Cancer Immunology Immunotherapy
影响因子:5.1
doi:10.1007/s00262-006-0187-x
Guinn, Barbara-ann; Norris, James S; Huang, LaiQiang; Farzaneh, Farzin; Kasahara, Noriyuki; Deisseroth, Albert B
肿瘤
基因治疗
肿瘤免疫
细胞生物学
发表日期：2006
文献求助 收藏

Normal and pathological functions of mammalian retroelements

哺乳动物逆转录元件的正常和病理功能

期刊:Proceedings of the National Academy of Sciences of the United States of America
影响因子:9.1
doi:10.1073/pnas.0505866102
Deisseroth, Albert
发表日期：2005
文献求助 收藏